Natural disease course of Crohn's disease ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study.
Auteur(s) :
Burisch, Johan [Auteur]
Kiudelis, Gediminas [Auteur]
Kupcinskas, Limas [Auteur]
Kievit Hendrika Adriana, Linda [Auteur]
Winther Andersen, Karina [Auteur]
Andersen, Vibeke [Auteur]
Salupere, Riina [Auteur]
Pedersen, Natalia [Auteur]
Kjeldsen, Jens [Auteur]
D''inca, Renata [Auteur]
Valpiani, Daniela [Auteur]
Schwartz, Doron [Auteur]
Odes, Selwyn [Auteur]
Olsen, Jongerð [Auteur]
Nielsen Kari, Rubek [Auteur]
Vegh, Zsuzsanna [Auteur]
Lakatos Peter, Laszlo [Auteur]
Toca, Alina [Auteur]
Turcan, Svetlana [Auteur]
Katsanos Konstantinos, H [Auteur]
Christodoulou Dimitrios, K [Auteur]
Fumery, Mathurin [Auteur]
Gower, Corinne [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Zammit Stefania, Chetcuti [Auteur]
Ellul, Pierre [Auteur]
Eriksson, Carl [Auteur]
Halfvarson, Jonas [Auteur]
Magro, Fernando [Auteur]
Duricova, Dana [Auteur]
Bortlik, Martin [Auteur]
Fernandez, Alberto [Auteur]
Hernandez, Vicent [Auteur]
Myers, Sally [Auteur]
Sebastian, Shaji [Auteur]
Oksanen, Pia [Auteur]
Collin, Pekka [Auteur]
Goldis, Adrian [Auteur]
Misra, Ravi [Auteur]
Arebi, Naila [Auteur]
Kaimakliotis Ioannis, P [Auteur]
Nikulina, Inna [Auteur]
Belousova, Elena [Auteur]
Brinar, Marko [Auteur]
Cukovic-Cavka, Silvija [Auteur]
Langholz, Ebbe [Auteur]
Munkholm, Pia [Auteur]
Kiudelis, Gediminas [Auteur]
Kupcinskas, Limas [Auteur]
Kievit Hendrika Adriana, Linda [Auteur]
Winther Andersen, Karina [Auteur]
Andersen, Vibeke [Auteur]
Salupere, Riina [Auteur]
Pedersen, Natalia [Auteur]
Kjeldsen, Jens [Auteur]
D''inca, Renata [Auteur]
Valpiani, Daniela [Auteur]
Schwartz, Doron [Auteur]
Odes, Selwyn [Auteur]
Olsen, Jongerð [Auteur]
Nielsen Kari, Rubek [Auteur]
Vegh, Zsuzsanna [Auteur]
Lakatos Peter, Laszlo [Auteur]
Toca, Alina [Auteur]
Turcan, Svetlana [Auteur]
Katsanos Konstantinos, H [Auteur]
Christodoulou Dimitrios, K [Auteur]
Fumery, Mathurin [Auteur]

Gower, Corinne [Auteur]

Lille Inflammation Research International Center - U 995 [LIRIC]
Zammit Stefania, Chetcuti [Auteur]
Ellul, Pierre [Auteur]
Eriksson, Carl [Auteur]
Halfvarson, Jonas [Auteur]
Magro, Fernando [Auteur]
Duricova, Dana [Auteur]
Bortlik, Martin [Auteur]
Fernandez, Alberto [Auteur]
Hernandez, Vicent [Auteur]
Myers, Sally [Auteur]
Sebastian, Shaji [Auteur]
Oksanen, Pia [Auteur]
Collin, Pekka [Auteur]
Goldis, Adrian [Auteur]
Misra, Ravi [Auteur]
Arebi, Naila [Auteur]
Kaimakliotis Ioannis, P [Auteur]
Nikulina, Inna [Auteur]
Belousova, Elena [Auteur]
Brinar, Marko [Auteur]
Cukovic-Cavka, Silvija [Auteur]
Langholz, Ebbe [Auteur]
Munkholm, Pia [Auteur]
Titre de la revue :
Gut
Nom court de la revue :
Gut
Numéro :
68
Pagination :
423-433
Date de publication :
2019-02-07
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
OBJECTIVE: The Epi-IBD cohort is a prospective population-based inception cohort of unselected patients with inflammatory bowel disease from 29 European centres covering a background population of almost 10 million ...
Lire la suite >OBJECTIVE: The Epi-IBD cohort is a prospective population-based inception cohort of unselected patients with inflammatory bowel disease from 29 European centres covering a background population of almost 10 million people. The aim of this study was to assess the 5-year outcome and disease course of patients with Crohn's disease (CD). DESIGN: Patients were followed up prospectively from the time of diagnosis, including collection of their clinical data, demographics, disease activity, medical therapy, surgery, cancers and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis. RESULTS: In total, 488 patients were included in the study. During follow-up, 107 (22%) patients received surgery, while 176 (36%) patients were hospitalised because of CD. A total of 49 (14%) patients diagnosed with non-stricturing, non-penetrating disease progressed to either stricturing and/or penetrating disease. These rates did not differ between patients from Western and Eastern Europe. However, significant geographic differences were noted regarding treatment: more patients in Western Europe received biological therapy (33%) and immunomodulators (66%) than did those in Eastern Europe (14% and 54%, respectively, P<0.01), while more Eastern European patients received 5-aminosalicylates (90% vs 56%, P<0.05). Treatment with immunomodulators reduced the risk of surgery (HR: 0.4, 95% CI 0.2 to 0.6) and hospitalisation (HR: 0.3, 95% CI 0.2 to 0.5). CONCLUSION: Despite patients being treated early and frequently with immunomodulators and biological therapy in Western Europe, 5-year outcomes including surgery and phenotype progression in this cohort were comparable across Western and Eastern Europe. Differences in treatment strategies between Western and Eastern European centres did not affect the disease course. Treatment with immunomodulators reduced the risk of surgery and hospitalisation.Lire moins >
Lire la suite >OBJECTIVE: The Epi-IBD cohort is a prospective population-based inception cohort of unselected patients with inflammatory bowel disease from 29 European centres covering a background population of almost 10 million people. The aim of this study was to assess the 5-year outcome and disease course of patients with Crohn's disease (CD). DESIGN: Patients were followed up prospectively from the time of diagnosis, including collection of their clinical data, demographics, disease activity, medical therapy, surgery, cancers and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis. RESULTS: In total, 488 patients were included in the study. During follow-up, 107 (22%) patients received surgery, while 176 (36%) patients were hospitalised because of CD. A total of 49 (14%) patients diagnosed with non-stricturing, non-penetrating disease progressed to either stricturing and/or penetrating disease. These rates did not differ between patients from Western and Eastern Europe. However, significant geographic differences were noted regarding treatment: more patients in Western Europe received biological therapy (33%) and immunomodulators (66%) than did those in Eastern Europe (14% and 54%, respectively, P<0.01), while more Eastern European patients received 5-aminosalicylates (90% vs 56%, P<0.05). Treatment with immunomodulators reduced the risk of surgery (HR: 0.4, 95% CI 0.2 to 0.6) and hospitalisation (HR: 0.3, 95% CI 0.2 to 0.5). CONCLUSION: Despite patients being treated early and frequently with immunomodulators and biological therapy in Western Europe, 5-year outcomes including surgery and phenotype progression in this cohort were comparable across Western and Eastern Europe. Differences in treatment strategies between Western and Eastern European centres did not affect the disease course. Treatment with immunomodulators reduced the risk of surgery and hospitalisation.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Équipe(s) de recherche :
Inflammatory digestive disease : pathophysiology and therapeutic targets developement
IBD and environnemental factors : epidemiology and functional analyses
IBD and environnemental factors : epidemiology and functional analyses
Date de dépôt :
2019-03-01T14:09:25Z
2023-12-13T14:50:19Z
2023-12-13T14:50:19Z